Form 8-K SALIX PHARMACEUTICALS For: Nov 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Salix Pharma (SLXP) Misses Q3 EPS by 3c; Issues Weak Q4 Outlook
November 6, 2014 4:26 PM ESTSalix Pharma (NASDAQ: SLXP) reported Q3 EPS of $1.53, $0.03 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $354.7 million versus the consensus estimate of $394 million.
Salix Pharma sees FY2014 EPS of $5.20, versus the consensus of $6.17. Salix Pharma sees FY2014 revenue of... More
